Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 22Prostatic Neoplasms, Castration-Resistant 2Metastatic Castration-resistant Prostate Cancer 2Urogenital Neoplasms 1Thrombocytopenia 1Prostatic Diseases 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Liver Neoplasms 1Kidney Neoplasms 1High-Risk Localized Prostate Cancer 1Glioma 1Glioblastoma 1Genital Neoplasms, Male 1Disease 1Cytopenia 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Hepatocellular 1Carcinoma 1Astrocytoma 1Anemia 1

Interventions

Prednisone 5Docetaxel 4niraparib 2enzalutamide 2darolutamide 2Pluvicto 2Abiraterone Acetate 2olaparib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1abiraterone 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1JNJ-64619178 1JNJ-64264681 1Dexamethasone 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × Pluvicto × 90 days × Clear all
NCT07587814 2026-05-14

COCORIVO

Centre Henri Becquerel

Phase NA Not yet recruiting
100 enrolled
Genitourinary

Carcinoma, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT07047118 2026-05-01

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Novartis

Phase 2 Active not recruiting
138 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡